|
Dr. Williams joined ZymoGenetics in 2004 as Chief Scientific Officer and Executive Vice President and is responsible for the company's research and development programs. Dr. Williams has held senior level positions at a number of notable biotechnology companies including Seattle Genetics Immunex Amgen and Genesis Research and Development a New Zealand based biotechnology company. As Executive Vice President and Chief Technology Officer at Immunex Dr. Williams played a significant role in the discovery and early development of Enbrel the first biologic approved for the treatment of rheumatoid arthritis. In addition Dr. Williams was a member of Immunex Corporation's Board of Directors. Before entering the biotechnology industry Dr. Williams served on the faculty of the Indiana University School of Medicine and worked in the Department of Laboratory Medicine at the Roswell Park Memorial Institute. Dr. Williams earned a B.S. magna cum laude in Biological Sciences from the University of Massachusetts Lowell and a Ph.D. in Physiology from the State University of New York at Buffalo. | 